Navigation Links
TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
Date:4/10/2013

WASHINGTON, D.C. April 9, 2013 The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, and presented today at the American Association for Cancer Research (AACR) Annual Meeting 2013.

Data for the study was generated at the Virginia G. Piper Cancer Center Clinical Trials, a partnership of TGen and Scottsdale Healthcare.

Dr. Daniel Von Hoff, TGen Physician-In-Chief and Chief Scientific Officer of Scottsdale Healthcare's Clinical Research Institute, will present A Phase 1 Study of BIND-014, a PSMA-targeted Nanoparticle Containing Docetaxel, in Patients with Refractory Solid Tumors during an AACR session at 1 p.m. EDT today at the Washington, D.C., Convention Center, Room 146.

Dr. Von Hoff, the study's Principal Investigator, will present complete Phase 1 clinical data of BIND-014, which is produced by BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND-014 is the company's lead drug candidate.

In 28 patients with advanced or metastatic solid tumors, BIND-014 with its targeted docetaxel Accurin was shown to be generally safe and well-tolerated at the established maximum dose of 60 mg/m2. BIND-014 showed encouraging signs of anti-tumor activity, including one complete response, three partial responses and five patients with stable disease lasting at least four, 12-week-plus cycles. In addition, the pharmacokinetic (PK) profile of BIND-014 was substantially different from the published PK of conventional docetaxel.

"This Phase 1 trial has successfully established the safety and tolerability profile and maximum tolerated dose of BIND-014 in patients with advanced or metastatic solid tumor cancers," said Dr. Von Hoff, F.A.C.P., TGen's Distinguished Professor. "There is a cri
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
8. ViroPharma to Participate in Two December Healthcare Investor Conferences
9. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
(Date:8/28/2014)... 28, 2014 The ability for organizations ... that will allow individuals to perform at the highest ... for employers looking to compete in this post–recession era. ... this trend, as the sector increasingly focuses on the ... which will have real results on the organization's development ...
(Date:8/28/2014)... Aug. 28, 2014   SunTrust Robinson Humphrey ... veterans to its equity research team in biotechnology ... expansion in equity research demonstrates our commitment to ... to enhance their investment decision making," said ... "We continue to make significant investments in differentiated ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... 2012 Codexis, Inc. (Nasdaq: CDXS ), ... of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced ... presenting at the Jefferies Global Clean Technology Conference, to ... 23, 2012 at 1:45 p.m. ET. A live webcast ...
... Pharmaceuticals, Inc. (Nasdaq: AVNR ) today announced that ... Conference. , Citi 2012 Global Health Care Conference ... February 29, 2012 , 9:00 a.m. ET ... presentation will be available at http://ir.avanir.com . ...
... Feb. 21, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: ... in the development, manufacturing, and marketing of branded generic ... will report its unaudited financial results for the fourth ... Wednesday, March 7, 2012, before the market opens in ...
Cached Biology Technology:Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012 2
(Date:8/29/2014)... available in German . ... organisms is considered the oldest form of communication. Acting ... for example, the sexual attraction between males and females. ... to coordinate reproductive behavior in males and females. Scientists ... the Algarve in Faro, Portugal, and at the Max ...
(Date:8/29/2014)... Boulder, Colo., USA - The rise of the Tibetan ... on Earth -- is important for both its profound ... In this study published in GSA Bulletin , ... -- "clumped" isotope thermometry -- using modern and fossil ... Zhada basin in southwestern Tibet. , Views range ...
(Date:8/28/2014)... study reports that an expansion of marine protected areas ... ecological functions. According to investigators from the Wildlife ... fish have focused on saving the largest numbers of ... provide key and difficult-to-replace ecological functions. , ... by fish species that also are food for millions ...
Breaking Biology News(10 mins):Ready for mating at the right time 2Ready for mating at the right time 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... to a collection of test tubes in her Iowa State ... they were holding very weak coffee. That meant microorganisms ... converting sugars into hydrocarbons, said Jarboe, an Iowa State assistant ... the sugars in those test tubes were produced by the ...
... Heavy and prolonged snowfall can bring about unexpected conditions ... in the Arctic, according to experts. A new international ... helps plants to grow bigger, heavy and prolonged snow can, ... of killer fungal strains. The research results, published in ...
... studies in this special issue document the substantial and growing ... the burden of a chikungunya outbreak in India. Luiz ... country,s worsening trend; from 1999-2009, where cases rose at 6.2% ... Carmen Perez and co-workers, reporting on dengue vector control ...
Cached Biology News:Iowa State hybrid lab combines technologies to make biorenewable fuels and products 2Iowa State hybrid lab combines technologies to make biorenewable fuels and products 3Arctic snow harbors deadly assassin 2World Health Organization releases latest Dengue Bulletin 2World Health Organization releases latest Dengue Bulletin 3World Health Organization releases latest Dengue Bulletin 4World Health Organization releases latest Dengue Bulletin 5World Health Organization releases latest Dengue Bulletin 6World Health Organization releases latest Dengue Bulletin 7World Health Organization releases latest Dengue Bulletin 8
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
... Kit contains a green fluorescent-labeled inhibitor, FAM-VAD-FMK, ... valylalanylaspartic acid (VAD) fluoromethyl ketone (FMK), a ... added to a population of cells, the ... covalently binds to a reactive cysteine residue ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... VersArray ChipWriter Pro system, 220-240 V, uses ... proteins, oligonucleotides, carbohydrates, lipids, and other biomolecules ... applications. This system can generate high-density arrays ... slide or greater than 57,000 spots per ...
Biology Products: